CF PharmTech, Inc. (02652.HK) bought back 24,000 H-shares on the Hong Kong Stock Exchange on 30 April 2026. The repurchase was executed at prices ranging from HKD 21.86 to HKD 22.26 per share, translating into a volume-weighted average cost of HKD 22.07 and a total consideration of HKD 0.53 million.

Following the transaction, issued shares (excluding treasury stock) decreased from 301.58 million to 301.56 million, while treasury shares rose from 641,000 to 665,000. The 24,000 shares repurchased represent 0.008 % of the company’s outstanding share capital at the opening balance on 28 April 2026. The total number of issued shares, including treasury shares, remained unchanged at 302.22 million.

The buyback forms part of a mandate granted on 16 December 2025, which authorises CF PharmTech to repurchase up to 30.22 million shares. Cumulative buybacks under this mandate now stand at 665,000 shares, equivalent to 0.22 % of the issued share base on the mandate date.

Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or disposal of treasury shares until 30 May 2026.